Trastuzumab combined with trimodality treatment does not improve outcomes for patients

(NRG Oncology) Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news